These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107 [TBL] [Abstract][Full Text] [Related]
6. Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia. Kizaki M; Muto A; Kinjo K; Ueno H; Ikeda Y J Natl Cancer Inst; 1998 Dec; 90(24):1906-7. PubMed ID: 9862629 [No Abstract] [Full Text] [Related]
7. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia. Au WY; Lang BH; Fong BM; Mao KJ; Tam S Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647 [No Abstract] [Full Text] [Related]
8. Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern? Firkin F Leuk Lymphoma; 2014 May; 55(5):977-8. PubMed ID: 24144311 [No Abstract] [Full Text] [Related]
9. Molecular targets of arsenic trioxide in malignant cells. Miller WH Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205 [TBL] [Abstract][Full Text] [Related]
10. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Barbey JT; Soignet S Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116 [No Abstract] [Full Text] [Related]
11. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia]. Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy]. Tajima M Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563 [No Abstract] [Full Text] [Related]